Puberty and type 1 diabetes

Diabetes and Metabolism

Volumn 27, Issue 4 II, 2001, Pages

  Acerini, L ^a   Williams, M ^a   Dunger, B ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Growth hormone; IGF 1; Insulin; Puberty; Type 1 diabetes

Indexed keywords

ACIPIMOX; ANTIDIABETIC AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; OCTREOTIDE; PIRENZEPINE; RECOMBINANT SOMATOMEDIN C; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PUBERTY; SCHOOL CHILD; SIDE EFFECT; WEIGHT GAIN;

EID: 0034854272     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Diabetes in adolescence
2. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin dependent diabetes mellitus: Diabetes Control, and Complications Trial
3. Relationship between insulin, insulin-like growth factor 1, and dehydroepiandrosterone sulfate concentrations during childhood, puberty, and adult life
4. Evidence for a role for insulin and growth hormone in the overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents
5. Puberty decreases insulin sensitivity
6. Increased insulin secretion in puberty: A compensatory response to reductions in insulin sensitivity
7. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes
8. Characterization of the insulin-antagonistic effect of growth hormone in man
9. Augmentation of growth hormone secretion during puberty: Evidence for a pulse amplitude-modulated phenomenon
10. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization
11. The effect of growth hormone on glucose metabolism and insulin secretion in man
12. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
13. Mechanism of free fatty acid-induced insulin resistance in humans
14. The direct and indirect effects of insulin on hepatic glucose production in vivo
15. Mediation of the hepatic effects of growth hormone by its lipolytic activity
16. Insulin resistance of puberty: A defect restricted to peripheral glucose metabolism
17. Increased overnight growth hormone concentrations in diabetics compared with normal adolescents
18. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type I (insulin dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning
19. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics
20. Somatomedin-C / IGF-1 measured by immunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls
21. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin dependent diabetes
22. Low serum somatomedin-c in insulin-dependent diabetes: Evidence for a postreceptor mechanism
23. Growth hormone receptor and serum binding protein: Cloning and expression
24. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa
25. Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type I (insulin dependent) diabetes mellitus
26. Loss of the normal relationships between growth hormone, growth hormone binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus
27. Insulin and variation in glucose levels modify the secretion rates of growth hormone independent insulin-like growth factor binding protein -I in the human hepatoblastoma cell line Hep G2
28. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin?
29. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: Possible contribution of insulin-like growth factor binding protein-I
30. Insulin-like growth factors I and II
31. Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro
32. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-1)
33. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus
34. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin dependent) diabetes mellitus
35. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries
36. Insulin doses in children using conventional therapy for insulin dependent diabetes
37. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus
38. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type I diabetes
39. Eating disorders in adolescents with IDDM. A controlled study
40. Sexual dimorphism in insulin sensitivity in adolescents with insulin-dependent diabetes mellitus
41. Microalbuminuria prevalence varies with age, sex, and puberty in children with type I diabetes followed from diagnosis in a longitudinal study
42. Prevalence of abnormal urinary albumin excretion in adolescents and children with insulin dependent diabetes: The MIDAC study
43. Albumin excretion rate, serum insulin-like growth factor-I and glomerular filtration rate in type I diabetes mellitus at puberty
44. The role of growth hormone in the development of diabetic retinopathy
45. Diabetes, diabetic angiopathy, and growth hormone
46. Insulin-like growth factor I acts as an agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor
47. Indications of low sex hormone binding globulin (SHBG) in young females with type I diabetes, and an independent association to microalbuminuria
48. Effect of diabetes and its control on insulin like growth factors in the young subject with type I diabetes
49. Adverse events and their association with treatment regimens in the diabetes control and complications trial
50. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF binding protein-3 in IDDM
51. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients
52. Does recombinant insulin-like growth factor I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence?
53. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type I diabetes
54. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile
55. RhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM
56. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus
57. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type I diabetes
58. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications?
59. Insulin-like growth factors. Studies in diabetics with and without retinopathy
60. Is insulin-like growth factor associated with diabetic retinopathy
61. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus
62. Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus
63. Early morning hyperglycemia in insulin dependent diabetes: Acute and sustained effects of cholinergic blockade
64. Reduced growth hormone secretion improves insulin sensitivity in adolescent girls with type I diabetes
65. Short term pirenzepine treatment is ineffective in suppressing 24-h growth hormone secretion in type I diabetes mellitus
66. Nocturnal use of pirenzepine by a group of insulin dependent juvenile diabetics
67. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism
68. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
69. Metformin and insulin: Is there a role for combination therapy?
70. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
71. Cellular mechanisms of insulin resistance